This treatment regime has significantly improved the outcome of the patients with metastatic HER2-positive breast cancer and is now the standard first-line treatment for HER2-positive metastatic breast cancer [11,19,23,24,25,176]. This evidence concerns the gene ERBB2 and breast carcinoma.